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The ex vivo cell therapy is based on the ability to 
isolate cells from a patient, expand them ex vivo 
before and after genetic modification, and 
administer them to the patient to stablish a stable 
graft of the infused cells and their progeny.  
 
This approach exploits ex vivo expanded T-cells or 
HSCs with genetic engineering to disrupt CCR5 
gene, increasing their resistance and immune 
activity against HIV. The main advantage is that the 
patient is not expose to the immunogenic vector.  
 
Pre-clinical studies 
 CCR5-deficient CD4 T Lymphocytes 
 Validation in Hematopoietic Stem Cells 
 CCR5/CXCR4 ZFNs Combined Strategy 
 
Clinical trials  
 Phase I/II study of safety and efficacy 
 Dose escalation phase I/II in patients with 
inadequate response to antiretroviral therapy 
 Phase I/II study with cyclophosphamide pre-
treatment 
 Phase II clinical trial 
Zinc-finger Nucleases  
 
Targeted genome editing is an approach that introduces stable genetic 
changes at preselected loci. Zinc-finger nucleases (ZFN) are chimeric 
proteins that function as a pair and consist in zinc finger peptides that 
bind to DNA specific sequences, fussed to the enzyme FokI. The 
double-stranded breaks are dominantly repaired by error-prone non-
homologous end joining (NHEJ), introducing mutations that produce 
truncated or non-functional proteins. 
Ex vivo Genome Editing 
Pre-clinical & Clinical Results 
 
Pre-clinical studies showed that in the presence of the selective pressure of a R5 HIV infection, ZFN modification conferred significant survival advantage and real 
protection to the treated T cells in humanized mice. Moreover, CCR5-negative HSCs retained full functionally and provided long-term resistance in all hematopoietic 
linage, even in critical compartments. Additionally, the combined disruption of both coreceptors gave protection in front of all tropism strains.  
 
Clinical trials make evident the therapeutic potential of the strategy. The infusion was generally safe and most of the patients showed increasing CD4 T cells counts, 
significant persistence of modified cells and their accumulation in the mucosa. Furthermore, the viral load importantly decreased even during the HAART interruption. 
 
The results suggest that viral eradication would probably require increased input and sustained generation of T cells carrying biallelic CCR5 disruption. Other 
improvements include the depletion of endogenous T cells before the infusion and the use of RNA electroporation to administrate the ZFNs into the lymphocytes.  
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Conclusion 
 
The huge amount of open fronts the HIV fight has, make evident the enormous effort that the scientific community is doing to eradicate the 
pandemic infection and get us closer to find a definitive cure. Regarding genome editing, future studies will be directed towards increasing the 
engraftment, demonstrating that it is possible to generate a stable population of HIV-resistant cells that can fight the virus and opportunistic 
infections thereby mimicking the characteristics of individuals that carry the natural mutation. In the future, multiple diseases may benefit from 
gene-editing strategies coupled to hematopoietic cell transplantation and immunotherapy approaches. Overall, these studies contribute to the 
birth of a new era in cell and gene therapy and bring us closer to the goal of precise site-specific gene editing and personalized medicine. 
Introduction 
 
The human immunodeficiency virus, known as HIV, is the lentivirus responsible of the acquired immune 
deficiency syndrome, AIDS, the main cause of death by infective agent around the world. HIV infects T-
lymphocytes and macrophages by the recognition of the cellular receptor CD4 and a chemokine coreceptor CCR5 
or CXCR4, being CCR5 the most common.  
 
Interestingly, individuals with homozygous 32bp deletion in the CCR5 gene are highly resistant to HIV-1. New 
therapies try to mimic the natural mutation and have proved that the establishment of a stable HIV resistance is 
possible thanks to the genome editing by zinc finger nucleases.  
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